Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis And Xuanwu Hospital Capital Medical University To Set Up Regeneration Lab

This article was originally published in PharmAsia News

Executive Summary

Sanofi-Aventis will cooperate with Xuanwu Hospital Capital Medical University to set up a regeneration laboratory to focus on research of the central nervous system, metabolic disorders and geriatric diseases. Since 2007, the company has established strategic partnerships with China's leading academic institutions. These include Tianjin Institute of Hematology and Blood Diseases Hospital, which comes under the Chinese Academy of Medical Sciences; and Shanghai Institute for Biological Sciences. Sanofi-Aventis disclosed that it is likely to launch a new oncology drug by the end of the year. The company's China operation currently prioritizes R&D and it will continue to build close partnerships with academic institutions. (Click here for more - Chinese Language)

You may also be interested in...



COVID-19 Partnerships Without Formal Contracts Pose Risks, From Potential Liability To IP Issues

Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.

‘Astonishing Results’ Or ‘Outrageous’ Claims? Peter Thomas Roth Fighting Bicoastal Class Actions

Plaintiffs against the prestige, “clinical” skin-care company are targeting anti-aging claims on its Rose Stem Cell Bio-Repair line and statements about hyaluronic acid’s ultra-moisturizing capabilities, used to market its Water Drench range. PTR faces false advertising class actions in California and New York federal courts, and the former case appears to be headed for trial.

Flagship, ARCH Close VC Funds Totaling $2.56bn

Flagship Pioneering raised $1.1bn to fund life science companies emerging from Flagship Labs. ARCH, another frequent start-up co-founder, raised two funds totaling $1.46bn to back early-stage biotech.

UsernamePublicRestriction

Register

SC072051

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel